Cancer Prevention Institute of California, 2201 Walnut Avenue, Suite 300, Fremont, CA 94538-2334, USA.
Br J Cancer. 2013 Jul 9;109(1):280-8. doi: 10.1038/bjc.2013.294. Epub 2013 Jun 11.
Solid organ transplant recipients have high risk of lymphomas, including non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL). A gap in our understanding of post-transplant lymphomas involves the spectrum and associated risks of their many histologic subtypes.
We linked nationwide data on solid organ transplants from the US Scientific Registry of Transplant Recipients (1987-2008) to 14 state and regional cancer registries, yielding 791 281 person-years of follow-up for 19 distinct NHL subtypes and HL. We calculated standardised incidence ratios (SIRs) and used Poisson regression to compare SIRs by recipient age, transplanted organ, and time since transplantation.
The risk varied widely across subtypes, with strong elevations (SIRs 10-100) for hepatosplenic T-cell lymphoma, Burkitt's lymphoma, NK/T-cell lymphoma, diffuse large B-cell lymphoma, and anaplastic large-cell lymphoma (both systemic and primary cutaneous forms). Moderate elevations (SIRs 2-4) were observed for HL and lymphoplasmacytic, peripheral T-cell, and marginal zone lymphomas, but SIRs for indolent lymphoma subtypes were not elevated. Generally, SIRs were highest for younger recipients (<20 years) and those receiving organs other than kidneys.
Transplant recipients experience markedly elevated risk of a distinct spectrum of lymphoma subtypes. These findings support the aetiologic relevance of immunosuppression for certain subtypes and underscore the importance of detailed haematopathologic workup for transplant recipients with suspected lymphoma.
实体器官移植受者患淋巴瘤的风险较高,包括非霍奇金淋巴瘤(NHL)和霍奇金淋巴瘤(HL)。我们对移植后淋巴瘤的认识存在一个空白,即其多种组织学亚型的范围和相关风险。
我们将美国器官移植受者科学注册处(1987-2008 年)的全国性实体器官移植数据与 14 个州和地区癌症登记处相关联,对 19 种不同的 NHL 亚型和 HL 进行了 791281 人年的随访。我们计算了标准化发病比(SIR),并使用泊松回归比较了受者年龄、移植器官和移植后时间的 SIR。
各亚型的风险差异很大,肝脾 T 细胞淋巴瘤、伯基特淋巴瘤、NK/T 细胞淋巴瘤、弥漫性大 B 细胞淋巴瘤和间变性大细胞淋巴瘤(全身和原发性皮肤形式)的风险显著升高(SIR 为 10-100)。HL、淋巴浆细胞性、外周 T 细胞和边缘区淋巴瘤的风险中度升高(SIR 为 2-4),但惰性淋巴瘤亚型的 SIR 没有升高。一般来说,年轻受者(<20 岁)和接受除肾脏以外的器官的受者的 SIR 最高。
移植受者经历了一系列明显升高的淋巴瘤亚型的风险。这些发现支持了某些亚型与免疫抑制相关的病因学相关性,并强调了对疑似淋巴瘤的移植受者进行详细血液病理学检查的重要性。